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Abstract
Purpose: Abnormal fatty acid (FA) synthesis is one of the common features of cancer. Fatty acid
synthase (FASN), a multifunctional enzyme playing a key role in biosynthesis of FA, is up-regulated
in prostate, breast, and lung carcinomas. Orlistat is a FDA-approved anti-obesity drug that inhibits the
thioesterase domain of FASN, interferes with cellular FA synthesis, can arrest tumor cell proliferation,
and induces tumor cell apoptosis. The current study was aimed to investigate themetabolic changes
associated with FASN inhibition by orlistat and to understand the molecular mechanisms behind the
observed metabolic changes in non-small cell lung carcinoma (NSCLC) cell lines.
Procedures: Changes in metabolite pools in four NSCLC cell lines (H441, H1975, H3255, and
PC14) with different mutational profiles were studied using NMR spectroscopy before and after
in vitro incubation with sub-toxic concentration of orlistat and [1-13C]D-glucose or [1,2-13C2]
choline. In vitro radiotracer accumulation assays in cells were performed with [3H]acetate, [14C]
fluoroacetate, and 2-deoxy-2-[18F]fluoro-D-glucose. In parallel, microarray profiling of genes
involved in the regulation of carbohydrate and lipid metabolism was performed.
Results: In orlistat-treated NSCLC cells, FASN inhibition results in characteristic changes in
intermediary metabolites (FAs, choline, phospholipids, and TCA cycle metabolites) as observed
by magnetic resonance spectroscopy. Further, FASN inhibition by orlistat induces multiple
adaptive changes in FA synthetic pathway and associated metabolic pathways, including
induction of ketone metabolism and glutaminolysis, as well as the up-regulation of 5' adenosine
monophosphate-activated protein kinase.
Conclusions: These observed changes in metabolic pools in orlistat-treated cells demonstrate the
critical role of fatty acid de novo synthesis and metabolism for cellular energy production, especially in
tumor cells with low glycolytic activity, which goes beyond thewidely accepted concept that FA synthesis
is important for cell membrane biosynthesis in rapidly proliferating tumor cells.
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Introduction
O verexpression of fatty acid synthase (EC 2.3.1.85,FASN) and increased magnitude of fatty acid (FA)
synthesis are common characteristics of many malignancies,
particularly those with poor prognosis [1]. The constitutive
over-expression of FASN in tumor cells is largely due to
dysregulation of signal transduction mechanisms that down-
regulate FASN expression in normal cells [2]. Numerous
studies have demonstrated high levels of FASN expression
in various malignant and pre-malignant lesions [3, 4],
including lung carcinomas [5].
Pharmacologic inhibition of FASN by small molecule
inhibitors or down-regulation of FASN gene expression
by RNAi results in apoptosis of cancer cells, inhibition
of tumor growth, and prolongation of survival of tumor-
bearing animals [2]. Several inhibitors of FASN catalytic
activity have been developed as chemotherapeutic agents.
Cerulenin and C75, which target the ketoacyl synthase
domain of FASN, were reported as effective small
molecular inhibitors of FASN activity in tumor cells
[6]. Orlistat is a β-lactone-containing inhibitor of the
thioesterase domain of FASN. Inhibition of FASN by
C75 and orlistat induces cell death in a variety of tumor
cell lines and effectively inhibits the growth of prostate
and breast carcinoma xenografts in mice [3, 7, 8]. In
contrast, a high level of FAs in the diet (i.e., due to
supplementation of omega-3 FAs or ﬁsh oil) increases
the incidence of cancer in mice with inﬂammatory bowel
disease [9]. Together these data conﬁrm the important
role of FASN in cancer development, maintenance, and
progression.
Although extensive research has been carried out to
investigate the potential of FASN as a promising therapeutic
target for cancer treatment, limited studies are available on the
metabolic consequences of FASN inhibition in cancer cells. In a
previous study, magnetic resonance spectroscopy (MRS) was
used to monitor FASN inhibition by orlistat, and phosphocho-
line (PC) was identiﬁed as a potential metabolic biomarker of
FASN inhibition [10]. The current study was aimed to
investigate the metabolic changes associated with FASN
inhibition in non-small cell lung cancer (NSCLC) cell lines
with various molecular genetic abnormalities that affect FASN
expression activity levels. Changes in the metabolic proﬁles of
the NSCLC cell lines in response to orlistat treatment were
studied using multinuclear MRS, which expanded previously
reported observations [10]. Further, to identify the molecular
mechanisms behind the observed metabolic changes determined
using MRS in orlistat-treated NSCLC cells, we used real-time
polymerase chain reaction (PCR) arrays to assess changes in the
magnitude of expression of various genes involved in the
regulation of cellular metabolism. The results of this study
demonstrated that FASN inhibition by orlistat triggered several
adaptive compensatory changes in several metabolic pathways
that could be used as pharmacodynamic biomarkers of FASN
inhibition for MRS and PET imaging.
Materials and Methods
Cell Lines and Culture Conditions
Human NSCLC cells H441, H1975, and H3255, PC14 were
obtained from American Type Culture Collection (ATCC, VA,
USA). The mutational characteristics of these cell lines are listed in
Table S1 in the “Electronic Supplementary Material”. Cells were
routinely cultured in DMEM/F-12 (Invitrogen) supplemented with
5 % FBS (Hyclone, Logan, UT) and 10,000 units/ml penicillin,
10,000 μg/ml streptomycin, and 25 μg/ml amphotericin B (Life
Technologies) at 37 °C in 5 % CO2.
Cytotoxicity Assay
The viability of cells in culture following incubation for 24 h with
different concentrations of orlistat was assessed using WST-1 assay
(Roche, Indianapolis, IN, USA) according to the manufacturer’s
protocol. Additional details are provided in the “Electronic
Supplementary Material”.
FASN Activity Assay
Following incubation of tumor cells with 30 μM orlistat or DMSO
for 24 h, protein extracts were obtained under non-denaturing
conditions. FASN activity was determined as described in the
“Electronic Supplementary Material”.
In Vitro Radiotracer Accumulation Studies
The rates of accumulation of 2-deoxy-2-[18F]ﬂuoro-D-glucose
([18F]FDG), [3H]acetate, and [14C]ﬂuoroacetate in different
NSCLC cells were determined using a triple-label in vitro
radiotracer accumulation assay as previously described [11].
Additional details are provided in the “Electronic Supplementary
Material”.
MRS Studies
For 13C labeling of glucose and choline, D-glucose (8.76 mM)
in the medium was replaced by equal concentrations of [1-13C]
D-glucose (Cambridge Isotopes, MA, USA) and unlabeled D-
glucose and choline chloride in the medium was replaced by
[1,2-13C2]choline chloride (Cambridge Isotopes, MA, USA)
(64.1 μM). H441, H1975, H3255, and PC14 cells were treated
with medium containing [1-13C]D-glucose and [1,2-13C2]choline
in the presence of 30 μM orlistat or DMSO for 24 h. Cells
(~3×107–4×107) were then extracted using a dual-phase
method as described previously [12]. Changes in concentrations
of individual metabolites in orlistat-treated cells were expressed
as %control. Additional details are provided in the“Electronic
Supplementary Material”.
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Gene Expression Analyses
The RNA was isolated from NSCLC cells and puriﬁed using
RNAeasy kit (Qiagen) and reverse-transcribed to cDNA using the
RT² First Strand cDNA Kit (SABiosciences, MD, USA). The
expression levels of 168 key genes involved in different metabolic
pathways related to FA synthesis and metabolism were determined
using custom-designed RT2 proﬁler PCR arrays (SABiosciences,
MD, USA) according to the manufacturer’s protocol. The fold
changes in gene expression levels were calculated with ΔΔCt
method using data analysis software provided by the manufacturer
(SABiosciences, MD, USA). Additional details are provided in the
“Electronic Supplementary Material”.
Statistical Analyses
The difference between control and orlistat-treated groups was
assessed using an unpaired two-tailed Student’s t-test, with differ-
ences considered signiﬁcant for pG0.05. Hierarchical clustering
with one Pearson correlation metric and complete linkage rule were
used for comparing the gene expression proﬁles of different
NSCLC cells following orlistat treatment.
Pearson correlation was used to determine the correlation
between rates of radiotracer accumulation and metabolic changes
as determined by MRS and gene expression proﬁles.
Results
Effect of Orlistat on Cell Viability
H441, H1975, H3255, and PC14 cells were treated with
different concentrations of orlistat ranging from 25 to
125 μM, and the effect of orlistat on cell viability was
determined by WST-1 assay as described. In all the cell lines
studied, treatment with orlistat did not have a signiﬁcant
effect on cell viability up to a concentration of 125 μM. A
concentration of 30 μM orlistat was selected for subsequent
studies, as it has been demonstrated that this dose
reduced cellular FA synthesis by ~75 % within 30 min,
as determined by the incorporation of [14C]acetate into
FAs [13].
Inhibition of FASN Activity by Orlistat in NSCLC
Cells
Treatment with 30 μM orlistat for 24 h resulted in a
signiﬁcant inhibition of FASN activity in H441 and H1975
cell lines. FASN activity decreased to 73±6 % in H441 and
76±7 % in H1975 cells (pG0.05), respectively. Orlistat
treatment inhibited FASN activity in H3255 cells but did not
reach statistical signiﬁcance (p00.06). However, in PC14
cells, orlistat treatment did not signiﬁcantly affect FASN
activity (Fig. 1).
In Vitro Accumulation of [3H]Acetate, [14C]
Fluoroacetate, and [18F]FDG
In all the cell lines studied, the rate of accumulation of [3H]
acetate was the highest, followed by [14C]ﬂuoroacetate,
whereas [18F]FDG was found to be the least accumulated
radiotracer (Fig. S1 in the “Electronic Supplementary
Material”). In particular, H3255 cells demonstrated the
highest accumulation rates of [3H]acetate and [14C]ﬂuoroa-
cetate and the lowest accumulation rate of [18F]FDG (Fig.
S1c in the “Electronic Supplementary Material”).
When the cells were treated with 30 μM orlistat for 24 h,
the accumulation rates of [3H]acetate, [14C]ﬂuoroacetate,
and [18F]FDG decreased signiﬁcantly in H441 and H1975
cells, as compared to control (pG0.05). However, in H3255
and PC14 cells, orlistat treatment did not signiﬁcantly affect
the accumulation rate of [3H]acetate, [14C]ﬂuoroacetate, and
[18F]FDG (Fig. S1 in the “Electronic Supplementary
Material”; Fig. 2).
To assess the magnitude of orlistat-induced changes in
the de novo FA synthesis vs. glycolysis, the accumulation
rates of [3H]acetate and [14C]ﬂuoroacetate were normalized
by that of [18F]FDG (Table S2 in the “Electronic Supple-
mentary Material”). The ratios of accumulation rates of [3H]
acetate versus [18F]FDG and [14C]ﬂuoroacetate versus [18F]
FDG were relatively higher in H3255 cells, but lower in
PC14, as compared to other cell lines. Following orlistat
treatment, the relative accumulation of [3H]acetate versus
[18F]FDG and [14C]ﬂuoroacetate versus [18F]FDG increased
signiﬁcantly in H441, H1975, and PC14. However, in
orlistat-treated cells, the ratio between the rates of accumu-
lation of [3H]acetate and [14C]ﬂuoroacetate did not change
signiﬁcantly, except for H1975 (Table S2 in the “Electronic
Supplementary Material”).
Changes in Metabolite Pools After Treatment
with Orlistat
To study the effect of orlistat-induced inhibition of FASN on
different metabolic pathways, such as glycolysis, FA synthesis,
and choline metabolism, the cells were labeled with [1-13C]D-
glucose and [1,2-13C2]choline or [2-
13C]acetate, as described
earlier. 13C MRS was performed in control and orlistat-treated
cells to assess changes in de novo synthesis of various
intermediary metabolites. 1H and 31P MRS were performed to
determine changes in the total pool of metabolites.
At baseline, in cells labeled with [1-13C]D-glucose and
[1,2-13C2]choline, the majority of the detected signal in
13C
MR spectra of water-soluble metabolites was observed from
13C-enriched metabolites, such as C3-alanine, C3-lactate,
C3-glutamate, C3-glutamine, C4-glutamate, C4-glutamine,
C3-aspartate, and C1 and C2-PC, α and β anomers of C1-
enriched glucose (Fig. 3a). The predominant signal in 13C
MR spectra of lipid fractions was from the methylene
carbons of de novo FAs (Fig. 3b).
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When labeled with [1-13C]D-glucose and [1,2-13C2]
choline, common metabolic differences between control
and orlistat-treated H441, H1975, and PC14 cells were
observed, such as increased accumulation of β-glucose (Glu-
β) and β-fructose 1,6-bisphosphate (βF16P) (Fig. 3c; Fig. S2
in the “Electronic Supplementary Material”) and decreased
levels of de novo FA and de novo and total phosphatidyl-
choline (Ptd.Cho.) However, H3255 cells did not exhibit any
of the metabolic changes observed in H441, H1975, and
PC14 cell lines. In orlistat-treated H3255 cells, a signiﬁcant
increase in the level of membrane phospholipids (CL/
Ptd.EA, Ptd.serine, and sphingomyelin) was observed by
31P MRS, but no signiﬁcant changes in de novo FA were
observed by 13C MRS (Fig. S2 in the “Electronic Supple-
mentary Material”). In contrast, orlistat-treated H441,
H1975, and PC14 cells exhibited a signiﬁcant decrease in
membrane phospholipid levels, including Ptd.inositol
(Fig. 3d; Fig. S2 in the “Electronic Supplementary
Material”).
Following orlistat treatment, signiﬁcantly higher total PC
levels were observed by 31P MRS in H441 and H1975 cells;
increased total choline levels were observed by 1H MRS in
H1975 cells. However, orlistat-treated PC14 cells exhibited
a decreased synthesis of de novo PC as compared to control
cells. Additionally, increased levels of C3-lactate were
observed in orlistat-treated H1975 and H3255 cells (Fig.
S2 in the “Electronic Supplementary Material”).
13C MRS with [2-13C]acetate labeling demonstrated that,
in orlistat-treated H441 cells, C3-glutamate and taurine
decreased signiﬁcantly, whereas N-acetyl amino acids
increased signiﬁcantly in orlistat-treated H1975 (Fig. 4a)
and PC14 cells (Fig. S2 in the “Electronic Supplementary
Material”). A signiﬁcant decrease in de novo FA synthesis
was also observed following orlistat treatment in H441,
H1975 (Fig. 4b), and PC14 cells, but not in H3255 cells
(Fig. S2 in the “Electronic Supplementary Material”).
Orlistat treatment resulted in increased labeling of C2- and
Fig. 1. Changes in enzymatic activity of FASN in orlistat-
treated NSCLC cells as compared to control (*pG0.05).
Fig. 2. Comparison of unidirectional influx rates Ki of a [3H]acetate, b [14C]fluoroacetate, and c [18F]FDG in control (DMSO) and
orlistat-treated NSCLC cells (*pG0.05).
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C4-glutamine in PC14 cells. Fig. 5a shows the heatmap of
changes in different metabolite levels as determined by 1H,
13C, and 31P MRS in orlistat-treated versus control NSCLC
cells labeled with [1-13C]D-glucose and [1,2-13C2]choline or
[2-13C]acetate. The hierarchical cluster analysis demonstrat-
ed clustering of H3255 cells farther apart from the other
three cell lines. The H441 and H1975 cells were clustered
much closer.
Changes in Gene Expression Proﬁles
After Treatment with Orlistat
Fig. 5b shows a heatmap of up+ or down− fold-regulation of
168 genes involved in key metabolic pathways related to FA
metabolism in different NSCLC cell lines treated with
orlistat as compared to control. Orlistat treatment resulted
in several characteristic changes in gene expression proﬁles,
including a signiﬁcant up-regulation of FASN in all the cell
lines studied and up-regulation of acetyl–coenzyme A
carboxylase alpha (ACACA), ATP-citrate lyase (ACLY),
hexokinase-2 (HK2), low-density lipoprotein receptor
(LDLR), acyl–CoA synthetase short-chain family member
2 (ACSS2), and 3-hydroxy-3-methylglutaryl-coenzyme A
synthase-1 (soluble) HMGCS1 and down-regulation of acyl–
CoA synthetase short-chain family member-1 (ACSS1) in
majority of the NSCLC cell lines studied (Fig. S3 in the
“Electronic Supplementary Material”). However, several
genes were down-regulated including fructose-1,6-bisphos-
phatase 1 and 2 (FBP1) and (FBP2) in H441 cells. A list of
genes expressing signiﬁcant changes in expression levels
following orlistat treatment in different NSCLC cell lines is
presented in Table S5 in the “Electronic Supplementary
Material”.
The hierarchical cluster analysis of the gene expression
proﬁles has also demonstrated that H3255 cells are clustered
farther apart from the other three cell lines, followed by PC14,
whereas H441 and H1975 cells were clustered together. An
extensive correlation analysis was performed to ﬁnd the
relationships between the in vitro accumulation rate of different
radiotracers, intermediary metabolite levels observed by MRS,
and the gene expression proﬁles. The heatmap of gene-
metabolite correlation coefﬁcients is shown in Fig. 6. Several
clusters of signiﬁcantly correlating genes and metabolites were
identiﬁed (Fig. S4 in the “Electronic Supplementary Material”)
and marked on the heatmap (Fig. 6).
In cluster-1A, changes in concentrations of C2-glutamine,
Lac/Thr, glycine, and C3-lactate, as well as de novo and total
Fig. 3. 13C MR spectra of a water-soluble metabolites, b lipid fractions, and 31P MR spectra of c water-soluble metabolites
and d lipid fractions of control and orlistat-treated H1975 cells incubated with [1-13C] D-glucose and [1,2-13C2]choline.
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lipid metabolites, were inversely correlated with changes in
the expression levels of genes involved in FA and lipid
metabolism (FASN, ACACB, ACSS2, ACLY, LDLR) and
other regulatory genes such as MAPK1, PIK3CA, and
PPARG which regulate FA storage and glucose metabolism
and BCL2L1 (Fig. S4-1a in the “Electronic Supplementary
Material”). In cluster-1B, changes in concentrations of lipid
metabolites and Glu-α, β-NTP, and amino acids (Fig. S4-1b
in the “Electronic Supplementary Material”) were directly
correlated with changes in expression levels of the same
genes as in cluster-1A (Fig. S4-1a in the “Electronic
Supplementary Material”).
Cluster-2A demonstrates the inverse correlation between
changes in concentrations of de novo and total lipid
metabolites and changes in the expression levels of genes
involved in FA and lipid metabolism (ACACA, AACS),
ketone metabolism (BDH1, OXCT1), insulin signaling
(IGF1R, IGF2), and other genes such as GLUD1, PRKCZ,
PCK1, and SLC2A4 (Fig. S4-2a in the “Electronic Supple-
mentary Material”). Cluster-2B shows that changes in
concentrations of metabolites derived from 31P MRS (Fig.
S4-2b in the “Electronic Supplementary Material”) were
directly correlated with changes in the expression levels of
the same genes in cluster-2A (Fig. S4-2a in the “Electronic
Supplementary Material”).
Changes in expression levels of genes, including
PRKAB1 and PRKCZ encoding regulatory sub-units of
AMPK—the key regulator of energy metabolism, SLC2A4
encoding GLUT-4, GLUD1, genes involved in FA and lipid
metabolism (ACACA, AACS), ketone metabolism (BDH1,
OXCT1), and insulin signaling (IGF1R, IGF2), were
inversely correlated with changes in concentrations of
metabolites in cluster-3A (Fig. S4-3a in the “Electronic
Supplementary Material”) and of de novo FA metabolites in
cluster-3B (Fig. S4-3b in the “Electronic Supplementary
Material”). Changes in the expression levels of genes
involved in glucose metabolism (HK2, SLC2A1, SLC2A9,
SLC2A11), EGFR, and CS were directly and inversely
correlated with changes in concentrations of amino acid
metabolites in cluster-4A (Fig. S4-4a in the “Electronic
Supplementary Material”) and that of de novo FA and 31P
MRS metabolites in cluster-4B (Fig. S4-4b in the “Electron-
ic Supplementary Material”), respectively.
Changes in concentrations of amino acids, lipid metabo-
lites, de novo FA, and de novo Ptd.Cho. in cluster-5A (Fig.
S4-5a in the “Electronic Supplementary Material”) and that
of de novo FA metabolites in cluster-5B (Fig. S4-5b in the
“Electronic Supplementary Material”) were inversely corre-
lated with the change in expression levels of genes involved
in insulin signaling (INS, IRS2), GLUD2, G6PC, PRKAG1
encoding regulatory subunit of AMPK, and SLC2A2
encoding GLUT-2. In cluster-6A, changes in concentrations
of βF16P and amino acids were inversely correlated with
changes in expression levels of genes involved in phospho-
lipid metabolism (CHDH, PCYT1B, PCTP, ACOX1,
ELOVL6) and other genes such as GSK3A, IRS1, PDK3,
and EGF (Fig. S4-6a in the “Electronic Supplementary
Material”). However, changes in concentrations of metabo-
lites in cluster-6B and de novo FA metabolites in cluster-6C
were directly correlated with changes in the expression
levels of these genes (Fig. S4-6b, c in the “Electronic
Supplementary Material”).
Fig. S4-7a, b in the “Electronic Supplementary Material”
demonstrates a direct correlation between changes in
concentrations of total as well as de novo FA and other
lipid metabolites with changes in the expression levels of
genes including those involved in lipid metabolism
(AACSL, ECHS1), glycolysis (PIK3R1, AKT1, PDK2,
GPD1, PKM2, and FBP2), and ERBB2. In cluster-8,
changes in concentrations of 31P MRS metabolites were
directly correlated with changes in the expression levels of
genes involved in FA and lipid metabolism (EHHADH,
Fig. 4. 13C MR spectra of a water-soluble metabolites and b lipid fractions of control and orlistat-treated H1975 cells
incubated with [2-13C]acetate.
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Fig. 5. Heatmaps of a fold-regulation values of 168 genes in orlistat-treated NSCLC cells relative to control as determined by
RT2-profiler PCR arrays and b relative changes in MRS-observed metabolite levels of orlistat-treated NSCLC cells as compared
to control.
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Fig. 6. Heatmap of correlation coefficients of fold-regulation values of 168 genes and relative changes of MRS-observed
metabolite levels of orlistat-treated NSCLC cells as compared to control.
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DGAT1, LPCAT1, LPCAT3, LPCAT4, CPT1A, CPT2,
SLC25A20), glycolysis, and tricarboxylic acid (TCA) cycle
(PDK1, PDK4, SUCLA, HK1, OGDH) (Supplementary Fig.
S4-8 in the “Electronic Supplementary Material”).
In cluster-9A, changes in concentrations of amino acid
and lipid metabolites were directly correlated with changes
in the expression levels of genes such as HIF1A, HMGCS2,
KHK, and IGFBP1 (Supplementary Fig. S4-9a in the
“Electronic Supplementary Material”), whereas changes in
the concentrations of metabolites in cluster-9B were inverse-
ly correlated with changes in the expression levels of these
genes (Fig. S4-9b in the “Electronic Supplementary Mate-
rial”). Changes in the expression levels of genes including
those involved in ketone metabolism (HMGCS1), cholester-
ol synthesis (HMGCR), glucose metabolism (SLC2A6), and
lipid metabolism (SREBF1) and other genes such as
VEGFA and JUN were inversely (Fig. S4-10a in the
“Electronic Supplementary Material”) and directly (Fig.
S4-10b in the “Electronic Supplementary Material”) corre-
lated with changes in the concentrations of metabolites in
clusters-10A and 10B, respectively. Fig. S4-11a, b in the
“Electronic Supplementary Material” demonstrate that
changes in the expression levels of genes involved in
choline and phospholipid metabolism (CHKA, ACSS1,
LPCAT2, ACADSB), AMPK regulatory sub-units
(PRKAA1, PRKAA2), and glucose transport and metabo-
lism (SLC2A10, SLC2A12, GCK) were inversely correlated
with changes in the concentrations of metabolites including
amino acids (alanine, Glu/Gln, glutamine, N-acetyl AA,
GABA) and βF16P (Fig. S4-11a in the “Electronic Supple-
mentary Material”) and directly correlated with changes in
the concentrations of metabolites in cluster-11B including de
novo FA metabolites (Fig. S4-11a in the “Electronic
Supplementary Material”).
Correlation analysis further demonstrated that the accu-
mulation rates of [3H]acetate (KiAce) and [
14C]ﬂuoroacetate
(KiFAce) were directly correlated with the mRNA levels of
FBP1, GPD1, PKM2, PTPN1, and BDH2 and inversely
correlated with ACSS2 (r90.8, pG0.05). The accumulation
rate of [18F]FDG (KiFDG) was directly correlated with PCK2
and HIF1A, whereas it was inversely correlated with
SLC2A4, DGAT1, EHHADH, CPT2, OXCT1, and BDH1
(r90.8, pG0.05). Both KiAce and KiFAce were also directly
correlated with the levels of several metabolites, such as
glycine, total FA, de novo FA, de novo Ptd.Cho., Ptd.
inositol, and total Ptd.Cho (r90.8, pG0.05).
Discussion
Non-invasive molecular imaging techniques such as positron
emission tomography (PET) and MRS can provide the
means for visualization and quantiﬁcation of FASN activity
in tumors, monitoring of pharmacodynamic effects, and
prediction of therapeutic responses in individual patients.
Several previous studies reported the application of PET
imaging with [18F]FDG or [11C]-acetate for monitoring
tumor therapy with C75 [14, 15]. However, PET imaging
has not been used for characterization of changes in tumor
metabolism resulting from orlistat-induced inhibition of
FASN due to uncertainty of pharmacodynamic changes in
metabolic pools and signal transduction pathways that could
serve as biomarkers of treatment response.
In the current study, the effect of FASN inhibition in the
cellular uptake of the metabolic precursors of fatty acids was
investigated for the ﬁrst time in NSCLC cell lines with
different molecular and genetic abnormalities that affect
FASN expression activity levels by comparing the in vitro
accumulation of [3H]acetate, [14C]ﬂuoroacetate (as a surro-
gate of [18F]ﬂuoroacetate), and [18F]FDG. In all the cell
lines studied, the predominant accumulation of [3H]acetate
and [14C]ﬂuoroacetate, as compared to [18F]FDG, demon-
strated that these cell lines have a relatively low glycolytic
activity and are more dependent on de novo FA synthesis for
their metabolic needs and membrane biosynthesis. A
signiﬁcant decrease in the accumulation of [3H]acetate and
[14C]ﬂuoroacetate relative to [18F]FDG was observed in
orlistat-treated H441 and H1975 cell lines, but not in H3255
and PC14. This is most likely due to the incomplete
inhibition of FASN activity in H3255 and PC14 cells by
30 μM of orlistat, as determined by FASN activity assay
(Fig. 1), which is due to the compensatory up-regulation of
FASN expression levels in these cell lines, as determined by
RT-PCR (Fig. 5b; Fig. S3 in the “Electronic Supplementary
Material”).
There are several possible reasons to the observed
decrease in [3H]acetate and [14C]ﬂuoroacetate accumulation
in orlistat-treated H441 and H1975 cell lines. During cellular
metabolism, acetate is activated into acetyl–CoA by acetyl–
CoA synthetase (ACS). ACSS1 and ACSS2 are the two
isoforms of ACS. ACSS1 is a mitochondrial enzyme that
produces acetyl CoA for oxidation in the TCA cycle.
Mitochondrial acetyl–CoA produced by ACSS1 becomes
citrate, which is transported into the cytosol for lipid
synthesis. ACSS2 is a cytosolic enzyme that converts acetate
to acetyl–CoA for the synthesis of FAs and cholesterol.
Other reports concluded that ACSS2 has no major role in
lipid biosynthesis in glycolytically active [18F]FDG-avid
tumor cells based on the observation of low [11C]acetate
accumulation [16]. In contrast, both ACSS1 and ACSS2
were highly expressed in cells with low glycolytic activity,
and both enzymes correlated well with [11C]acetate accu-
mulation [16]. These ﬁndings conﬁrm that ACS is one of the
key enzymes in radio-labeled acetate accumulation and
acetate-dependent lipid biosynthesis in tumors with a low
glycolytic phenotype [16]. In the current study, in all the
NSCLC cells studied, ACSS2 expression was higher than
that of ACSS1, both in control and orlistat-treated cells,
demonstrating the high dependency of these cell lines on de
novo FA for their metabolic needs. The highest level of
ACSS2 expression was observed in H3255 cells, which
explains the highest accumulation of [3H]acetate and [14C]
ﬂuoroacetate, as compared to other cell lines. The observed
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down-regulation of ACSS1 following orlistat treatment
explains the decreased [3H]acetate and [14C]ﬂuoroacetate
accumulation in H441 and H1975 cells. However, ACSS2
was up-regulated in orlistat-treated H441, H1975, and PC14
cells, in addition to the up-regulation of several genes in FA
metabolic pathway such as ACACA (that mediates conver-
sion of acetate to acetyl–coA), FASN, and ACLY (Table S5
in the “Electronic Supplementary Material”). We hypothe-
size that the observed up-regulation of several genes
encoding lipogenic enzymes in orlistat-treated cells is a
compensatory adaptive mechanism to meet the increased
demand for de novo FA. However, this demand was unmet
in all the NSLC cell lines studied, which manifested as a
decrease in de novo synthesis of FA as observed by 13C
MRS (Fig. S3 in the “Electronic Supplementary Material”).
Inhibition of FASN by orlistat caused a decrease in the
accumulation of not only [3H]acetate and [14C]ﬂuoroacetate
but also of [18F]FDG, especially in H441 and H1975 cell
lines. This observation can be explained as follows. The
uptake and utilization of glucose is controlled by a multitude
of factors participating in the increased aerobic glycolysis of
cancers. [18F]FDG accumulation depends on the level of
expression activity of glucose transporters (GLUTs) and
subsequent phosphorylation by hexokinases (HKs) [17].
Several reports have indicated that [18F]FDG accumulation
reﬂects the coordinated expression of GLUTs and activity of
HKs, although uncoupling of GLUTs and HKs activities in
some cancers has been described as well [18–20]. Also, it
has been demonstrated that [18F]FDG uptake decreased in
cancer cells undergoing apoptosis [21]. In the present study,
PC14 cells at baseline demonstrated the highest expression
of HK2 and GLUT1, which explains the signiﬁcantly higher
accumulation of [18F]FDG in these cells as compared to that
in other cell lines. In orlistat-treated NSCLC cells, the rate of
accumulation of [18F]FDG negatively correlated with
GLUT4 expression, while HK1 and HK2 were signiﬁcantly
up-regulated in H441 and H1975 cells. Also, HK2 was up-
regulated selectively in PC14 cells. The observed transcrip-
tional up-regulation of these metabolic enzymes in orlistat-
treated H441, H1975, and PC14 cells in spite of the
decreased accumulation of [18F]FDG is part of the compen-
satory adaptive mechanisms of response to orlistat treatment.
However, this compensatory response was insufﬁcient to
increase the glycolytic activity in orlistat-treated H441,
H1975, and PC14 cells, as demonstrated by the down-
regulation of FBP1 and FBP2 and the accumulation of [13C]
glucose and the glycolytic intermediate βF16bP. These
observations explain the observed decrease in glucose
utilization and decreased accumulation of [18F]FDG in these
cell lines in response to orlistat treatment. Importantly,
decreased accumulation of [18F]FDG in orlistat-treated H441
and H1975 cells was observed despite increased mRNA
levels of GLUT1, GLUT4, HK-1, HK-2, VEGF, and HIF1-
a, which demonstrates that the up-regulation of transcription
of genes encoding for these enzymes did not however
translate into increased enzymatic activity [21].
Orlistat-treated H1975 cells exhibited the largest buildup
of βF16bP (445±45 %) as compared to other cell lines. This
may possibly be due to the PIK3CA mutation in H1975 cells
in addition to the other common mutations observed in H441
and PC14 cells (Table S1 in the “Electronic Supplementary
Material”). Mutant PIK3CA activates AKT signaling, which
up-regulates FASN and promotes glycolysis [22]. However,
inhibition of FASN by orlistat may have possibly resulted in
decreased AKT signaling and inhibition of glycolysis.
Another possible reason for decreased glycolysis in H441,
H1975, and PC14 cells could be the signiﬁcant up-regulation
of PRKAB1, PRKAG1, and PRKAG2 that encode the
regulatory sub-units of AMPK. AMPK activation is reported
to decrease the rate of glycolysis, either by inducing the
glycolysis inhibitor TIGAR [TP53 (tumor protein 53)-
induced glycolysis and apoptosis regulator] via p53 activa-
tion or by AMPK-dependent mTOR suppression [23, 24].
Thus, the up-regulation of AMPK activity may explain, at
least in part, the reason for decreased glycolytic activity in
orlistat-treated cells despite transcriptional up-regulation of
GLUTs and HKs. The results of the current study are
consistent with previous report that the knockdown of FASN
suppresses genes involved in glycolysis, Krebs–TCA cycle,
and oxidative phosphorylation [25].
Following orlistat treatment, all the NSCLC cell lines
labeled with either [13C]glucose or [2-13C]acetate exhibited
decreased levels of de novo FA, except for H3255. This
observation is also consistent with previous reports [6, 10,
13, 26]. The extent of decrease in de novo FA was almost
the same, whether the cells were labeled with either [1-13C]
glucose or [2-13C]acetate. Orlistat-treated H3255 cells
exhibited a trend (albeit not statistically signiﬁcant) for
increased incorporation of [13C]glucose-derived 13C label
into the de novo synthesized FA, but with no signiﬁcant
change in [2-13C]acetate incorporation. H3255 cells did not
exhibit the majority of characteristic metabolic changes
associated with FASN inhibition by orlistat as observed in
the other cell lines. Such difference is possibly due to an
insigniﬁcant inhibition of FASN activity in H3255 cells by
30 μM of orlistat in 24 h (Fig. 1) because these cells express
threefold more FASN mRNA at baseline as compared to
other NSCLC cell lines studied. Interestingly, PC14 cells
demonstrated most of the MRS-detectable metabolic
changes observed in H441 and H1975 cell lines despite
insigniﬁcant inhibition of FASN enzyme activity by orlistat
treatment. These results demonstrate that H3255 cells are
more resistant to FASN inhibition by orlistat and are
pharmacodynamically less responsive to orlistat treatment.
The results of the hierarchical clustering analysis of the gene
expression proﬁles matched very well with the in vitro
radiotracer accumulation and MRS experiments. Both
cluster analyses demonstrated that H3255 cells were clus-
tered farther apart from other NSCLC cell lines studied,
which adds to the explanation of higher resistance to FASN
inhibition and lack of pronounced compensatory responses
observed in other cell lines.
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The decreased levels of de novo and total Ptd.Cho. in
orlistat-treated NSCLC cell lines observed with MRS are in
agreement with previous reports, indicating decreased
membrane phospholipid metabolism following FASN inhi-
bition by orlistat [10, 13]. The increased levels of de novo
and total PC in orlistat-treated H441 and H1975 cells may be
explained, at least in part, by the compensatory up-
regulation of choline kinase (CHKA) in H441 and phospho-
lipase (PLD1) in H1975 cells (Table S5 in the “Electronic
Supplementary Material”). Inhibition of FASN by orlistat
and the consequent changes in metabolic pool cause several
adaptive changes in cellular biochemistry, which manifest in
either up- or down-regulation of expression of different
metabolic enzymes (Figs. S5 and S6 in the “Electronic
Supplementary Material”). Relationships between de novo
FA and phospholipid metabolites derived from the 13C MRS
of NSCLC cells incubated with either [1-13C]D-glucose or
[2-13C]acetate with the same sub-clusters of genes involved
in several signaling pathways indicate that the observed
results are irrespective of the source of 13C enrichment (Fig.
S4-5a, b and 9-7a, b in the “Electronic Supplementary
Material”). The direct correlation of changes in levels of
13C-labeled amino acid metabolites with changes in the
expression levels of HK2 and genes encoding GLUTs,
SLC2A1, SLC2A9, and SLC2A11 suggests co-regulation
(Fig. S4-4a in the “Electronic Supplementary Material”).
However, it should be noted that these genes are inversely
correlated with the de novo FA metabolites (Fig. S4-4b in
the “Electronic Supplementary Material”; Cluster-4b) due to
the compensatory up-regulation of some of these genes in
response to FASN inhibition by orlistat.
Additionally, the direct correlation of the genes involved
in glycolysis such as FBP2, GPD1, PDK2, and PKM2 with
metabolites in clusters-7A and 7B (Fig. S4-7a, b in the
“Electronic Supplementary Material”) is consistent with the
inhibition of glycolysis in orlistat-treated NSCLC cells.
Inhibition of glycolysis is further evidenced by the increased
accumulation of glycolytic intermediate βF16P, as observed
both by both 31P and 13C MRS. In Fig. S4-8 in the
“Electronic Supplementary Material”, genes involved in
FA, lipid, and ketone metabolism and glucose transport are
grouped together in one major cluster, which clearly
demonstrates that these pathways are closely related to each
other and that FASN inhibition by orlistat affects multiple
pathways. The inverse relationship of FASN activity with
levels of expression of INS, IGF2, IGF1R, IRS1, IRS2, and
IGFBP1 (Fig. S4-2a, 3a, 5a, 5b, 6a, and 9b in the “Electronic
Supplementary Material”) demonstrates that de novo FA and
lipid metabolites are feedback regulated by insulin signaling
pathway as reported earlier [27]. Insulin is an important
regulator of FASN which not only increases the rate of
FASN gene transcription but also increases gene expression
and enzymatic activity [28]. The direct correlation of de
novo FA and lipid metabolites with the expression levels of
PIK3R1 and AKT1 underlines the importance of PI3K/Akt
pathway in the regulation of de novo FA synthesis (Fig. S4-
7a, b). The direct correlation of de novo lipid metabolites
with ERBB2 (Fig. S4-7a, b in the “Electronic Supplemen-
tary Material”) is also consistent with previous reports
regarding the transcriptional regulation of FASN by EGF
through ERBB2 [29].
One of the important genes involved in lipogenesis from
ketone bodies in adipose tissue is AACS (acetoacetyl–CoA
synthetase, EC 6.2.1.16), which catalyzes the production of
acetoacetate for synthesis of cholesterol and FA [30]. The
observed inverse correlation between the magnitude of
changes in AACS expression with changes in concentration
of metabolites in cluster-2A (Fig. S4-2a in the “Electronic
Supplementary Material”) suggests that FASN inhibition by
orlistat in NSCLC cells induces compensatory up-regulation
of AACS to satisfy the increasing demand for FA. However,
this increased demand was unmet, as evidenced by
decreased levels of de novo FA metabolites in 13C MRS.
Furthermore, the up-regulation of PRKAB1 (Fig. S4-3b in
the “Electronic Supplementary Material”) and PRKAG1
(Fig. S4-5b in the “Electronic Supplementary Material”)
encoding regulatory sub-units of AMPK observed in orlistat-
treated cells demonstrates the importance of FASN and FA
metabolism in the production of cellular energy sources.
This observation is consistent with the previous report on
activation of AMPK by inhibition of FASN by C93 in
human ovarian cancer cells [31]. The inverse correlation of
de novo FA and phospholipid metabolites with the expres-
sion level of HMGCS1, HMGCS2, HMGCR, BDH1, and
OXCT1 (Fig. S4-2a, 3b, 9b, and 10a in the “Electronic
Supplementary Material”) suggests that orlistat treatment in
NSCLC cells activates alternative metabolic pathways for
energy production such as ketone and cholesterol synthesis
as a compensatory response to FASN inhibition. The inverse
correlation of (Ki) [3H]acetate and (Ki) [14C]ﬂuoroacetate
with the expression level of ACSS2 also demonstrates the
compensatory up-regulation of ketogenesis in response to
orlistat-induced inhibition of de novo FA synthesis.
In summary, inhibition of FASN by orlistat induces multiple
adaptive changes in FA synthetic pathway and associated
metabolic pathways, including induction of ketone metabolism
and glutaminolysis. Furthermore, inhibition of FASN by
orlistat results in the up-regulation of AMPK which demon-
strates the critical role of FA metabolism in cellular energy
production, which is compensated in part by induction of
alternative metabolic pathways, such as ketone metabolism.
These observations expand the widely accepted concept that
FA synthesis is important for cell membrane biosynthesis,
especially in tumor cells with low glycolytic activity. The
results of this study expanded the current knowledge of the
molecular mechanisms of FASN inhibition which is essential
in the development of non-invasive biomarkers for therapeutic
monitoring of FASN inhibition.
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